Summer Student Placement Underway at Amprologix
14 August 2025This summer we’ve been pleased to welcome Rutendo Mupfumi from the University of Plymouth to the Amprologix lab. As part…
This summer we’ve been pleased to welcome Rutendo Mupfumi from the University of Plymouth to the Amprologix lab. As part…
Amprologix joins a global network of innovators We're proud to announce that Amprologix is one of the 103 finalists selected…
Mat Upton, CSO, presented the latest results from ongoing research at ESCMID Global 2025. ESCMID Global 2025 - the Congress of…
Mat Upton, CSO, presented new data at the 9th AMR conference in Basel on 25th February. It was suggested that…
Amprologix will be attending the Investival Showcase in London on 18th November 2024 Amprologix will be attending the Investival Showcase in…
November 2021 Amprologix have contracted two leading Commercial Research Organisations to conduct pre-clinical work on lead compound, epidermicin NI01. Amprologix have contracted two leading Commercial Research Organisations to conduct pre-clinical work on lead compound, epidermicin NI01. A formulation was developed for delivery of NI01 to the nasal cavity and this was shown to retain antimicrobial […]
We are delighted to be working with Adrian Gare and Alex Starling at FRP, who have a great track record in early stage financing and bring a wealth of life science sector experience to the team.
Having been based in the Marine Building at Plymouth University for the last 2-years, the company is now moving to the Derriford Research Facility to accommodate our expansion plans as we transition into the clinical phase of our antibiotic discovery programmes.
Amprologix CSO collaborates with Dr Max Ryadnov from the UK’s National Physical Laboratory, to publish new data on the novel mode of action of epidermicin NI01. Findings are reported in the August issue of iScience.
